Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3595890 | 0.98 | OPRM1 (0.73) | OPRM1KMT2AOPRD1 | |
| SCHEMBL2227341 | 0.86 | KMT2A (0.64) | OPRM1KMT2AOPRD1 | |
| SCHEMBL1285120 | 0.84 | OPRM1 (0.68) | OPRM1KMT2AOPRD1 | |
| SCHEMBL4657165 | 0.82 | OPRM1 (0.71) | OPRM1KMT2A | |
| SCHEMBL3157118 | 0.82 | OPRM1 (0.97) | OPRM1KMT2A | |
| SCHEMBL1284714 | 0.82 | OPRM1 (0.71) | OPRM1KMT2A | |
| SCHEMBL3321621 | 0.82 | OPRM1 (0.66) | OPRM1KMT2A | |
| SCHEMBL5166604 | 0.82 | OPRM1 (0.97) | OPRM1KMT2A | |
| SCHEMBL1284273 | 0.82 | OPRM1 (0.71) | OPRM1KMT2AOPRD1 | |
| SCHEMBL432561 | 0.82 | OPRM1 (0.59) | OPRM1KMT2AOPRD1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105349593-B | A kind of preparation method of pethidine hydrochloride | 浙江汇能生物股份有限公司 | 2019-01-25 | — | — | CN | claimed |
| US-9249159-B2 | Composition for treating hepatitis C virus, regulating phosphorylation of replicase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-02-02 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-20140219960-A1 | NOVEL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C VIRUS, REGULATING PHOSPHORYLATION OF REPLICASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2014-08-07 | — | — | US | claimed |
| EP-1385421-A4 | IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING MICROELECTRODES WITH MICROVOLTAMMETRY | UNIV CITY (US) | 2007-01-24 | — | — | EP | claimed |
| US-7112319-B2 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2006-09-26 | — | — | US | claimed |
| EP-1385421-A2 | IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING MICROELECTRODES WITH MICROVOLTAMMETRY | The Research Foundation Of the City university of New York (US) | 2004-02-04 | — | — | EP | claimed |
| CN-1119322-C | Process for alkylation of alkyl- or benzylcyanogen derivatives in presence of trialkylamines or -phosphines | AVENTIS PHARMACEUTICALS GERMAN (DE) | 2003-08-27 | — | — | CN | claimed |
| EP-0924196-B1 | Process for the alkylation of alkyl- or benzonitrile in the presence of trialkyl amines or phosphines | AVENTIS PHARMA GMBH (DE) | 2003-06-18 | — | — | EP | claimed |
| US-20030032001-A1 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2003-02-13 | — | — | US | claimed |
| WO-2002082970-A2 | DIAGNOSIS AND TREATMENT OF NEURAL DISEASE AND INJURY USING MICROVOLTAMMETRY | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2002-10-24 | — | — | WO | claimed |
| US-6143896-A | ALKYLATION OF NITRILE COMPOUND WITH SUBSTITUTED OR UNSUBSTITUTED ALKYL HALIDE OR DIALKYLSULFATE IN PRESENCE OF TRIALKYLOR ARYL AMINE OR PHOSPHINE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-07 | — | — | US | claimed |
| CN-1222505-A | Process for alkylation of alkyl- or benzylcyanogen derivatives in presence of trialkylamines or -phosphines | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-07-14 | — | — | CN | claimed |
| EP-0924196-A1 | Process for the alkylation of alkyl- or benzonitrile in the presence of trialkyl amines or phosphines | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-06-23 | — | — | EP | claimed |
| WO-2025123013-A1 | COMPOSITIONS FOR TREATING ADDICTION, DEPENDENCE, WITHDRAWAL, AND/OR OPIOID INDUCED HYPERALGESIA | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250009706-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | CASE WESTERN RESERVE UNIVERSITY | 2025-01-09 | — | — | US | disclosed |
| US-4066764-A | 1,4-Dihydro-2H-isoquinoline derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-03 | — | — | US | disclosed |
| US-4049655-A | 1,4-Dihydro-2H-isoquinoline derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3980655-A | Basically substituted 1,4-dihydro-2H-isoquinoline derivatives and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140219960-A1 | NOVEL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C VIRUS, REGULATING PHOSPHORYLATION OF REPLICASE | PRKCA, EIF2AK2, PRKCB | OPRM1 3748/4885KMT2A 2757/4885OPRD1 3129/4885 |
| US-20250009706-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885KMT2A 1352/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.